Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer. [electronic resource]
Producer: 20200203ISSN:- 2363-8915
- Aged
- Antineoplastic Agents -- administration & dosage
- Cyclin-Dependent Kinase 4 -- antagonists & inhibitors
- Drug Resistance, Neoplasm -- drug effects
- Drug Screening Assays, Antitumor
- Female
- High-Throughput Nucleotide Sequencing
- Humans
- Mutation
- Ovarian Neoplasms -- diagnosis
- Piperazines -- administration & dosage
- Pyridines -- administration & dosage
- Retinoblastoma Binding Proteins -- genetics
- Tumor Suppressor Protein p53 -- genetics
- Ubiquitin-Protein Ligases -- genetics
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.